Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 65Genitourinary 65Gastrointestinal 49Thoracic 48Other hematologic neoplasm 47Breast 41Plasma cell 37Head & Neck 25CNS 22Sarcoma 20Myeloid 16Gynecologic 16Dermatologic 13Other solid neoplasm 10Endocrine 7Tumor-Agnostic 3NET 3Classical hematology 1

Conditions

Neuroendocrine Tumors 3

Interventions

pembrolizumab 1pazopanib 1lenvatinib 1X-Rays 1Specimen Handling 1Salts 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × NET × 30 days × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT00569127 2026-05-26

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

National Cancer Institute (NCI)

Phase 3 Active not recruiting
427 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
45 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡